NONINTERVENTIONAL EXTENSION STUDY FOR PATIENTS TREATED IN STUDY R5459-RT-1944 WITH REGN5459 OR REGN5458 (BCMA CD3 BISPECIFIC ANTIBODIES) WHO RECEIVE A KIDNEY TRANSPLANT

Brief description of study

The primary objective of the study is to assess adverse events (AEs) and serious adverse events (SAEs) in kidney transplant recipients previously treated with REGN5459 or REGN5458 in the R5459-RT-1944 study. The primary endpoint for this study is the incidence of AEs and SAEs over a 12-month period, starting at the time of kidney transplantation.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions:
Medical Research
Age: - 99 Years
Gender: All

Kidney transplant recipient enrolled in research study R5459-RT-1944 and received investigational product treatment.

Updated on 09 Mar 2024. Study ID: 851581

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).